Obsidian Therapeutics Inc.(OBX)

Biotechnology · Cambridge, MA

$13.31-0.53 (-3.83%)

Delayed quote: Oct 6, 2026, 3:55 PM EDT

Price/OCF Ratio: N/A

Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.

The Price/OCF ratio is N/A as of 2026-10-06T19:58:14.922Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:58:14.922Z.

Quote observation: 2026-10-06T19:55:24.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 13,843,997
TTM operating cash flow: N/A

FMP input reference: 0fde8dae4c5ae63ee7b35c7e6e46bba2fdf5d6d5db310b32cf0eb41a7e17e840

P/E Ratio|P/FCF Ratio|Operating Cash Flow|Operating Margin|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

OBX Price/OCF Ratio Metrics

PRICE/OCF RATIO

N/A

OBX Competitors' Price/OCF Ratio

OBX

Obsidian Therapeutics Inc.

Current

Market Cap

$13.84M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SINT

Sintx Technologies, Inc.

vs OBX

Market Cap

$13.86M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLSM

Pulsenmore Ltd. Ordinary Shares

vs OBX

Market Cap

$14.05M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

OPTH

Optimi Health Corp.

vs OBX

Market Cap

$13.48M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CTXR

Citius Pharmaceuticals, Inc.

vs OBX

Market Cap

$13.31M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HIND

Vyome Holdings, Inc.

vs OBX

Market Cap

$14.46M

Price/OCF Ratio

27.57

TTM Avg

28.16

3Y Avg

28.16

5Y Avg

28.16

INAB

IN8bio, Inc.

vs OBX

Market Cap

$13.14M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KPTI

Karyopharm Therapeutics Inc.

vs OBX

Market Cap

$14.78M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PASG

Passage Bio, Inc.

vs OBX

Market Cap

$12.77M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KTTA

Pasithea Therapeutics Corp.

vs OBX

Market Cap

$14.97M

Price/OCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	PRICE/OCF RATIO	TTM	3Y	5Y
Obsidian Therapeutics Inc. (OBX)	$13.84M	N/A	N/A	N/A	N/A
Sintx Technologies, Inc. (SINT)vs ›	$13.86M	N/A	N/A	N/A	N/A
Pulsenmore Ltd. Ordinary Shares (PLSM)vs ›	$14.05M	N/A	N/A	N/A	N/A
Optimi Health Corp. (OPTH)vs ›	$13.48M	N/A	N/A	N/A	N/A
Citius Pharmaceuticals, Inc. (CTXR)vs ›	$13.31M	N/A	N/A	N/A	N/A
Vyome Holdings, Inc. (HIND)vs ›	$14.46M	27.57	28.16	28.16	28.16
IN8bio, Inc. (INAB)vs ›	$13.14M	N/A	N/A	N/A	N/A
Karyopharm Therapeutics Inc. (KPTI)vs ›	$14.78M	N/A	N/A	N/A	N/A
Passage Bio, Inc. (PASG)vs ›	$12.77M	N/A	N/A	N/A	N/A
Pasithea Therapeutics Corp. (KTTA)vs ›	$14.97M	N/A	N/A	N/A	N/A

Operating Cash Flow Valuation

P/OCF Ratio

N/A

P/FCF Ratio

N/A

Price/OCF Ratio Formula & Definition

P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Price/OCF Ratio: N/A

OBX Price/OCF Ratio Metrics

OBX Competitors' Price/OCF Ratio

Operating Cash Flow Valuation

Price/OCF Ratio Formula & Definition

Related Metrics